VE Pharma Inc Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: VE Pharma Inc Pharmaceutical Import Records from India — 4 Products, $1.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

VE Pharma Inc — Pharmaceutical Importer Profile (2026) | 4 Products, $1.9M Trade | TransData Nexus

VE Pharma Inc

Pharmaceutical Importer · Philippines · Oncology Focus · $1.9M Total Trade · DGFT Verified

VE Pharma Inc is a pharmaceutical importer based in Philippines with a total trade value of $1.9M across 4 products in 3 therapeutic categories. Based on 153 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. VE Pharma Inc sources from 1 verified Indian supplier, with Vexxa Lifesciences Private Limited accounting for 100.0% of imports.

VE Pharma Inc — Import Portfolio & Supplier Network

VE Pharma Inc import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to VE Pharma Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Vexxa Lifesciences Private Limited	$9.0M	1,853	100.0%

VE Pharma Inc sources from 1 verified Indian supplier across 787 distinct formulations. The sourcing is highly concentrated — Vexxa Lifesciences Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does VE Pharma Inc Import?

Formulation	Value	Ships
Vexdo 80 (docetaxel injection (80MG/2ML)	$267.7K	16
Vexpinem 500 (imipenem + cilastatin INJ)	$160.7K	24
Capvex 500 (capecitabine tablets USP	$130.1K	25
Capvex 500 (capecitabine tablets USP	$122.1K	22
Capvex 500 tabs (capecitabine tablets	$104.3K	17
Vexplatin 50 (oxaliplatin injection BP	$98.1K	20
Vexer 75 (pregabalin capsules 75 MG)	$96.7K	22
Doxvex 50 (doxorubicin hydrochloride	$91.8K	15
Merovex 1000 (meropenem for injection	$86.9K	10
Vexdo 80 docetaxel injection 80MG/2mlbch no-dcih23b09-b manufacturing dt-aug-2023	$83.3K	4
Vexlev 500 (levetiracetam tablets USP	$81.4K	6
Ervex 150 (erlotinib tablets 150 MG)	$76.9K	6
Merovex 1000 (meropenem for injection	$71.8K	14
Vexel 100 INJ (paclitaxel injection 100MG) batch no-pcib25ab02-a mfg dt-feb-2025 exp	$71.0K	4
Mevex 500 (pemetrexed lyophilized	$70.1K	8

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Docetaxel	Oncology	$1.1M	81	1.5%	12
2	Imipenem	Advanced Antibiotics	$434.2K	45	1.3%	16
3	Erlotinib	Advanced Oncology	$327.4K	21	6.9%	2
4	Gefitinib	Advanced Oncology	$34.2K	6	0.5%	11

VE Pharma Inc imports 4 pharmaceutical products across 3 categories into Philippines totaling $1.9M.

VE Pharma Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

VE Pharma Inc. is a pharmaceutical importer and distributor based in Makati City, Philippines. Established on November 23, 2012, the company specializes in the importation, marketing, and distribution of pharmaceutical products, including prescription drugs, medical devices, and nutraceuticals. VE Pharma Inc. operates as a subsidiary of VE Pharma, a healthcare group founded in 1994 with a significant presence across six countries in Asia: Cambodia, Laos, Vietnam, Philippines, Sri Lanka, and Thailand. The group's headquarters are located in Bangkok, Thailand.

In the Philippines, VE Pharma Inc. plays a pivotal role in the pharmaceutical supply chain by importing and distributing a diverse range of finished pharmaceutical formulations. The company's extensive portfolio includes products from renowned global healthcare companies such as Vitabiotics, Glenmark Pharmaceuticals, Meyer Organics, Kopran, Medley, and Vexxa Lifesciences. With a dedicated team of over 450 employees, VE Pharma Inc. leverages its local expertise to effectively navigate regulatory landscapes and establish strong relationships with healthcare institutions, clinics, retail pharmacies, and medical professionals throughout the region.

2Distribution Network

VE Pharma Inc. operates from two primary locations in the Philippines:

Unit 20A, 20th Floor, The World Centre
Sen. Gil Puyat Avenue, Bel Air, Makati City, Manila, Philippines

Units 7 & 8, 31st Floor, Zuellig Building
Makati Avenue corner, Paseo de Roxas, Brgy. Urdaneta, Makati City, 1225, Philippines

These strategically located offices facilitate efficient coordination and distribution of pharmaceutical products across the country. VE Pharma Inc. collaborates with various logistics partners to ensure timely and reliable delivery of products to healthcare providers and retailers nationwide. While the company's primary focus is on the Philippine market, its affiliation with the VE Pharma group enables potential expansion and distribution opportunities within the broader Asia-Pacific region.

3Industry Role

VE Pharma Inc. serves as a pharmaceutical importer and distributor within the Philippines' healthcare sector. The company is not classified as a primary wholesaler, parallel importer, hospital supplier, or logistics intermediary. Instead, it focuses on importing finished pharmaceutical formulations from international suppliers and distributing them to various stakeholders in the Philippine healthcare system. This role is crucial in ensuring the availability of a wide range of pharmaceutical products to meet the diverse needs of patients and healthcare providers across the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — VE Pharma Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

VE Pharma Inc. demonstrates a high level of sourcing concentration, importing 100% of its pharmaceutical products from a single supplier: Vexxa Lifesciences Private Limited. This exclusive sourcing strategy indicates a deep and strategic partnership between VE Pharma Inc. and Vexxa Lifesciences, potentially leading to favorable terms, consistent product quality, and streamlined logistics. However, such dependency also introduces risks associated with supply chain disruptions, regulatory changes, or operational challenges faced by the sole supplier. The absence of alternative suppliers may limit VE Pharma Inc.'s ability to mitigate these risks effectively. The shipment data, comprising 1,853 shipments from Vexxa Lifesciences, suggests a stable and ongoing relationship, yet the lack of diversification in sourcing could pose challenges in maintaining a resilient supply chain.

2Supply Chain Resilience

The resilience of VE Pharma Inc.'s supply chain is closely tied to the stability and reliability of Vexxa Lifesciences Private Limited, its sole supplier. The extensive number of shipments (1,853) indicates a well-established and consistent supply relationship. However, the absence of backup suppliers introduces vulnerability to potential disruptions, such as production delays, quality control issues, or geopolitical factors affecting trade routes. The company's focus on a single supplier may limit its flexibility in responding to unforeseen challenges. Additionally, the reliance on a single source may impact VE Pharma Inc.'s ability to negotiate favorable terms or adapt to changing market conditions.

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

In the Philippines, the Food and Drug Administration (FDA) is the primary regulatory authority overseeing the importation, registration, and distribution of pharmaceutical products. The FDA ensures that all pharmaceutical products meet the required safety, efficacy, and quality standards before they are made available to the public. Key legislation governing pharmaceutical imports includes the Food, Drug, and Cosmetic Act (Republic Act No. 3720) and its subsequent amendments, which provide the legal framework for the regulation of drugs and health products in the country. The marketing authorization pathway for Indian generics involves obtaining FDA approval through the submission of a New Drug Application (NDA) or a Certificate of Product Registration (CPR), which requires comprehensive documentation, including clinical trial data, manufacturing information, and labeling details.

2Import Licensing & GMP

Import licensing requirements in the Philippines mandate that all pharmaceutical products imported into the country must be registered with the FDA. This process involves submitting detailed product information, including manufacturing licenses, certificates of analysis, and Good Manufacturing Practice (GMP) certificates. The FDA recognizes GMP certifications from reputable international bodies, such as the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), provided they meet the FDA's standards. Indian exporters seeking to supply VE Pharma Inc. must ensure that their manufacturing facilities hold valid GMP certifications from recognized authorities and that their products comply with the FDA's import regulations. Additionally, VE Pharma Inc. must possess a valid wholesale distribution authorization from the FDA to legally distribute pharmaceutical products within the Philippines.

VE Pharma Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

VE Pharma Inc.'s product strategy focuses on importing and distributing a diverse range of pharmaceutical formulations across three therapeutic categories: Oncology, Advanced Antibiotics, and Advanced Oncology. The company's top five imported products include Docetaxel, Imipenem, Erlotinib, Gefitinib, and Capecitabine, which are integral to the treatment of various cancers and infectious diseases. This strategic focus aligns with the growing demand for advanced therapeutic options in the Philippines, driven by an increasing prevalence of chronic diseases and a rising awareness of specialized treatments among healthcare providers and patients. By concentrating on these therapeutic areas, VE Pharma Inc. aims to address critical healthcare needs and establish a strong presence in the market.

2Sourcing Profile

VE Pharma Inc. primarily sources its pharmaceutical products from Vexxa Lifesciences Private Limited, an Indian manufacturer. This sourcing strategy emphasizes the importation of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than raw Active Pharmaceutical Ingredients (APIs) or bulk drugs. The focus on finished formulations allows VE Pharma Inc. to offer ready-to-use products that meet the specific therapeutic needs of the Philippine market. India's well-established pharmaceutical industry, characterized by its adherence to international quality standards and competitive pricing, makes it an attractive sourcing partner for VE Pharma Inc.

Frequently Asked Questions — VE Pharma Inc

What products does VE Pharma Inc import from India?

VE Pharma Inc imports 4 pharmaceutical products across 3 categories. Top imports: Docetaxel ($1.1M), Imipenem ($434.2K), Erlotinib ($327.4K), Gefitinib ($34.2K).

Who supplies pharmaceuticals to VE Pharma Inc from India?

VE Pharma Inc sources from 1 verified Indian suppliers. The primary supplier is Vexxa Lifesciences Private Limited (100.0% of imports, $9.0M).

What is VE Pharma Inc's total pharmaceutical import value?

VE Pharma Inc's total pharmaceutical import value from India is $1.9M, based on 153 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does VE Pharma Inc focus on?

VE Pharma Inc imports across 3 categories. The largest: Oncology (58.9%), Advanced Antibiotics (22.4%), Advanced Oncology (18.7%).

Get Full VE Pharma Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

VE Pharma Inc

VE Pharma Inc — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to VE Pharma Inc?

What Formulations Does VE Pharma Inc Import?

What Products Does VE Pharma Inc Import?

Top Products by Import Value

VE Pharma Inc Therapeutic Categories — 3 Specializations